The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Latest updates in the CLL treatment landscape
Toby Eyre, MD, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), Oxford University Hospitals NHS Foundation Trust, Oxford, UK, outlines developments in the treatment of chronic lymphocytic leukemia (CLL) over the past few years, in particular highlighting the introduction of targeted inhibitors such as Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors. Dr Eyre gives an overview of the use of these drugs in clinical practice and comments on the need for further investigation to determine the optimal sequencing of these novel therapies. Dr Eyre also discusses unmet needs, highlighting the potential role of chimeric antigen receptor (CAR) T-cell and cellular therapies, as well as transplantation and reversible BTK inhibitors.
